Rossari Biotech Q3 Results 2025 on 22 Jan, 2025: profit falls by 7.82% YOY, profit at ₹31.7 crore and revenue at ₹512.73 crore

Rossari Biotech Q3 Results 2025:Rossari Biotech declared their Q3 results on 21 Jan, 2025, revealing a mixed performance for the quarter. The company's revenue increased by 10.56% year-over-year (YoY), reaching ₹ 512.73 crore. However, profit saw a decline of 7.82% YoY, totaling ₹ 31.7 crore. In comparison to the previous quarter, Rossari's revenue grew by 2.89%, while profit decreased by 10.27%. This decline in profit is attributed to rising operational costs, as the Selling, General & Administrative expenses rose by 9.61% quarter-over-quarter (q-o-q) and 37.06% YoY. Rossari Biotech Q3 Results The operating income also faced challenges, down by 8.53% q-o-q and 4.38% YoY. The Earnings Per Share (EPS) for Q3 was reported at ₹ 5.72, reflecting a decrease of 7.89% YoY. Rossari Biotech has experienced a -3.55% return in the last week, a -0.42% return over the past six months, and a 3.24% year-to-date return. Currently, Rossari Biotech holds a market capitalization of ₹ 4441.79 crore, with a 52-week high of ₹ 972.7 and a low of ₹ 656.95. As of 22 Jan, 2025, out of five analysts covering the company, one analyst has given a Hold rating, while four analysts have recommended a Strong Buy. The consensus recommendation for Rossari Biotech as of the same date is to Strong Buy. Rossari Biotech Financials Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff .